about
RGD-Binding Integrins in Head and Neck Cancers.Intramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactones.Function and antagonism of beta3 integrins in the development of cancer therapy.Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products.RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.Manganese(III) acetate mediated synthesis of oxygen heterocycles. Influence of copper(II) salts on product distribution.Kinetic and thermodynamic control of axial chirality in biaryl-derived fused oxazolidine lactams exploiting a centre-axis relay of unit efficiency.Synthesis of the originally proposed structures of elatenyne and an enyne from Laurencia majusculaThe changing faces of halogenated marine natural products: total synthesis of the reported structures of elatenyne and an enyne from Laurencia majusculaFunctionalized cyclobutenes via multicomponent thermal [2 + 2] cycloaddition reactionsSolid-Phase Synthesis of Duocarmycin Analogues and the Effect of C-Terminal Substitution on Biological ActivityExploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity
P50
Q33832735-AD40B401-A85C-4D0F-B4C1-A96CD9FB6FECQ37343701-849F6D8E-B659-4CD6-A1A9-D0A8528597CEQ37515522-CB466FA4-AF8C-4B2C-B1A9-95156D27C71BQ37630689-3E42E243-8F8E-4613-AB92-33EFED423407Q38161395-EA86F785-2E84-44A6-B1EC-98AF9FBB48B0Q38191051-B91D5408-E9DB-4B92-88D4-4C752DD0C067Q39127374-43552EE8-5A6D-4D22-B56D-BFDC798F0CF9Q39266629-FA2FB2BC-1298-4D5B-B48B-B783CF3B82FAQ44807792-41305547-035F-4CA7-BEA7-202EE98E67A7Q46895521-707F1144-204B-4E05-AC36-FE97D57E3DA5Q60327462-1A1CC50C-B7DE-4FD1-9C62-0D23ED7EEE39Q79197718-EDABB6F0-F9EA-4A7D-8B8A-6547273E1C70Q81175137-AD8D4125-F22D-4D14-87A9-EF5BB523E665Q86103324-A6A9ED8F-3F1B-4593-BDFD-B55E6493EBF1Q91046566-6F6BD01F-6963-4622-9EBC-5D47918B7040
P50
description
researcher ORCID ID=0000-0003-4111-2132
@en
wetenschapper
@nl
name
Helen M Sheldrake
@en
Helen M Sheldrake
@nl
type
label
Helen M Sheldrake
@en
Helen M Sheldrake
@nl
prefLabel
Helen M Sheldrake
@en
Helen M Sheldrake
@nl
P108
P106
P31
P496
0000-0003-4111-2132